product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein, CF
catalog :
1875-CD-050
quantity :
50 ug
price :
443 USD
more info or order :
R&D Systems product webpage
citations: 20
Reference
Adhikari E, Lu P, Kang Y, McDonald A, Pruszynski J, Bates T, et al. Diverging maternal and infant cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy. bioRxiv. 2023;: pubmed publisher
Bates T, Lu P, Kang Y, Schoen D, Thornton M, McBride S, et al. BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. Cell Rep. 2022;41:111544 pubmed publisher
An S, Yang B, Jang G, Kim D, Kim J, Oh S, et al. Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy. Nat Commun. 2022;13:5669 pubmed publisher
Bates T, Lu P, Kang Y, Schoen D, Thornton M, McBride S, et al. BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age. medRxiv. 2022;: pubmed publisher
Rogel A, Ibrahim F, Thirdborough S, Renart Depontieu F, Birts C, Buchan S, et al. Fcγ receptor-mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies. JCI Insight. 2022;7: pubmed publisher
Kitanaga Y, Yamajuku D, Kubo S, Nakamura K, Maeda M, Seki M, et al. Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus. Int Immunopharmacol. 2021;101:108343 pubmed publisher
Aitken E, Damelang T, Ortega Pajares A, Alemu A, Hasang W, Dini S, et al. Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. elife. 2021;10: pubmed publisher
Vanhove B, Duvaux O, Rousse J, Royer P, Evanno G, Ciron C, et al. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2. Eur J Immunol. 2021;51:1412-1422 pubmed publisher
Zekri L, Vogt F, Osburg L, M xfc ller S, Kauer J, Manz T, et al. An IgG-based bispecific antibody for improved dual targeting in PSMA-positive cancer. EMBO Mol Med. 2021;13:e11902 pubmed publisher
Blundell P, Lu D, Wilkinson M, Dell A, Haslam S, Pleass R. Insertion of N-Terminal Hinge Glycosylation Enhances Interactions of the Fc Region of Human IgG1 Monomers with Glycan-Dependent Receptors and Blocks Hemagglutination by the Influenza Virus. J Immunol. 2019;202:1595-1611 pubmed publisher
Arce Vargas F, Furness A, Litchfield K, Joshi K, Rosenthal R, Ghorani E, et al. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. Cancer Cell. 2018;33:649-663.e4 pubmed publisher
Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018;10:678-691 pubmed publisher
Zhang D, Whitaker B, DEREBE M, Chiu M. Fc?RII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody. MAbs. 2018;: pubmed publisher
Järnum S, Runström A, Bockermann R, Winstedt L, Crispin M, Kjellman C. Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy. Mol Cancer Ther. 2017;16:1887-1897 pubmed publisher
Meuris L, Santens F, Elson G, Festjens N, Boone M, Dos Santos A, et al. GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotechnol. 2014;32:485-9 pubmed publisher
Xie J, Yamniuk A, Borowski V, Kuhn R, Susulic V, Rex Rabe S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. J Immunol. 2014;192:4083-92 pubmed publisher
Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, et al. Increasing Fc?RIIa affinity of an Fc?RIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs. 2014;6:409-21 pubmed publisher
Franco A, Damdinsuren B, Ise T, Dement Brown J, Li H, Nagata S, et al. Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors. J Immunol. 2013;190:5739-46 pubmed publisher
Williams E, Tutt A, French R, Chan H, Lau B, Penfold C, et al. Development and characterisation of monoclonal antibodies specific for the murine inhibitory Fc?RIIB (CD32B). Eur J Immunol. 2012;42:2109-20 pubmed publisher
Richards J, Karki S, Lazar G, Chen H, Dang W, Desjarlais J. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008;7:2517-27 pubmed publisher
product information
brand :
R&D Systems
master code :
1875-CD
SKU :
1875-CD-050
product name :
Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein, CF
unit size :
50 ug
seo description :
The Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein, CF from R&D Systems is derived from NS0. The Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein, CF has been validated for the following applications: Binding Activity.
target :
Fc gamma RIIB/C (CD32b/c)
category :
Proteins and Enzymes
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS.
conjugate :
Unconjugated
dilution :
Binding Activity
purity :
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie« Blue Staining.
species :
Human
observed molecular weight :
25-35 kDa, reducing conditions
theoretical molecular weight :
21 kDa
gene symbol :
FCGR2B
details of functionality :
Measured by its ability to bind human IgG with an estimated Kd 200 nM.
endotoxin note :
<1.0 EU per 1 ╡g of the protein by the LAL method.
top caption :
Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein Binding Activity
accessionNumbers :
P31994
applications :
Binding Activity
source :
NS0-derived Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein, CF
USD :
443 USD
alt names :
CD32;CD32B;FCG2;FcgammaRIIb;FCGR2;FCGR2B;FCGR2C;FcGRIIB;FcRII-c;IGFR2;Low affinity immunoglobulin gamma Fc region receptor II-b, CD32b, CD32c, FCGR2B, FCGR2C, FcgRIIB, FcgRIIC, FCRIIB, FCRIIC
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 3 months, -20 to -70 ░C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.